TrialScientific reports2022

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms.

Lan Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.